Reuters logo
BRIEF-Galapagos announces two Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease
March 10, 2017 / 6:57 AM / 9 months ago

BRIEF-Galapagos announces two Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease

March 10 (Reuters) - Galapagos Nv

* announces two new phase 2 studies investigating filgotinib in small bowel Crohn’s disease as well as in fistulizing Crohn’s disease

* studies are being led by filgotinib collaboration partner Gilead Sciences Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below